Skip to main content

Table 2 Univariate survival analysis of LINE-1 methylation level and clinicopathological parameters with respect to overall survival

From: Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma

Parameters

 

Hazard ratio (95% C.I.)

P-value

LINE-1 methylation status

  

0.017

Q4 (n = 43)

Reference

 

Q3 (n = 43)

1.575 (0.561–4.602)

0.320

Q2 (n = 43)

3.369 (1.328–8.551)

0.011

Q1 (n = 43)

3.400 (1.349–8.570)

0.009

LINE-1 methylation status

Q3, Q4 (n = 86)

  

Q1, Q2 (n = 86)

2.643 (1.443–4.482)

0.002

pTNM staging

  

0.145

I (n = 43)

Reference

 

II (n = 38)

1.636 (0.739–3.622)

0.224

III (n = 30)

0.543 (0.173–1.709)

0.297

IV (n = 61)

1.602 (0.768–3.342)

0.209

T staging

  

0.044

pT1 (n = 48)

Reference

 

pT2a (n = 38)

1.809 (0.866–3.777)

0.114

pT2b (n = 14)

2.344 (0.929–5.913)

0.071

pT3 (n = 47)

0.941 (0.420–2.107)

0.883

pT4 (n = 25)

0.433 (0.123–1.524)

0.192

N staging

pN0 (n = 133)

  

pN1 (n = 39)

2.328 (1.304–4.157)

0.004

M staging

pM0 (n = 161)

  

pM1 (n = 11)

1.482 (0.533–4.118)

0.451

Gross type

  

0.076

Mass forming (n = 141)

Reference

 

Periductal infiltrative (n = 8)

0

0.964

Intraductal growth (n = 18)

0.134 (0.018–0.971)

0.047

Mixed (n = 5)

2.672 (0.827–8.638)

0.101

Lymphatic emboli

Absent (n = 102)

  

Present (n = 70)

2.519 (1.429–4.438)

0.001

Vascular invasion

Absent (n = 95)

  

Present (n = 77)

1.111 (0.634–1.945)

0.714

Perineural invasion

Absent (n = 118)

  

Present (n = 54)

0.386 (0.181–0.822)

0.014

Tumor border

Expanding (n = 32)

  

Infiltrative (n = 140)

2.133 (0.846–5.375)

0.108

Tumor differentiation

  

0.083

Well (n = 23)

Reference

 

Moderate (n = 94)

9.405 (1.283–68.943)

0.027

Poor (n = 55)

9.671 (1.290–72.518)

0.027

Chemotherapy and/or radiotherapy

No (n = 120)

  

Yes (n = 52)

0.979 (0.534–1.792)

0.944